Skip to main content

Table 1 Preclinical studies of CAR-NK presented at ASH 2024

From: CAR-NK cell therapy: latest updates from the 2024 ASH annual meeting

Diseases

NK cell source

Target

Reference

Acute myeloid leukemia

PB

MSLN

[7]

Acute myeloid leukemia

PB

CLL-1

[8]

Acute myeloid leukemia

PB

CD19

[11]

B-cell lymphoma

NK92 cell line

CD19; IL-15; CCL-21

[6]

Multiple myeloma

iPSC

GPRC5D

[9]

  1. CCL-21: C-C motif chemokine ligand 21; CIML: cytokine-induced memory-like; CLL-1: C-type lectin-like molecule-1; GPRC5D: G protein-coupled receptor, class C, group 5, member D; IL-15: interleukin-15; iPSC: induced-pluripotent stem cells; MSLN: mesothelin; PB: peripheral blood